Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Part of paid clinical trials in ‘Aiea, Hawaii.

Sponsor
Hawaii Pacific Health
Study ID
NCT00424710
Phase
PHASE1
Status
Completed

Conditions

  • Polypoidal Choroidal Vasculopathy

Eligibility Criteria

Sex
ALL
Age
25 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.

Key Dates

First listed
Jan 19, 2007
Start date
Jan 31, 2007
Status verified
Nov 2014
Primary completion
Sep 30, 2010
Completion
Sep 30, 2010

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Single Arm study
    Single arm study: Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year

Primary Outcome Measure

Efficacy Measured by the proportion of subjects who lose fewer than 15 letters in visual acuity at 6 and 12 month compared with baseline [ Time Frame: 1 year ]

Locations (2)

FacilityCityStateZIPSite coordinators
The Retina Center at Pali Momi‘AieaHawaii96701-
Retina Consultants of HawaiiHonoluluHawaii96817-

Find similar trials in ‘Aiea, HI

By research site
The Retina Center at Pali Momi· ‘Aiea, HIRetina Consultants of Hawaii· Honolulu, HI

Related Studies